A Phase Ib Study of Fruquintinib in 3rd Line mCRC

NCT01975077 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: fruquintinib

Sponsor

Hutchison Medipharma Limited

Collaborators

[object Object]
[object Object]